The Friendship Bench Plus Trial
NCT06384209 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 296
Last updated 2025-11-20
Summary
The goal of this randomised controlled trial is to enhance the Friendship Bench intervention with antidepressants in adults with moderate to severe depression. The main questions it aims to answer are:
1. Is the combination of the Friendship Bench with nurse-led antidepressants prescribing superior to the Friendship Bench alone?
2. What are the barriers and enablers for the prescription of antidepressants by nurses in primary care?
Type of study: Randomized controlled superiority trial
Participants will be randomly selected and allocated into the control arm or intervention arm. Participants in the control arm will receive six sessions of the Friendship Bench Problem Solving Therapy while those in the intervention arm will receive the Friendship Bench intervention plus Fluoxetine (Sertraline for breastfeeding women).
Conditions
- Major Depressive Disorder
- Severe Depressive Episode Without Psychotic Symptoms
Interventions
- DRUG
-
Fluoxetine
The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 20mg Fluoxetine. The nurse will then dispense the antidepressants for two weeks.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study visit, Fluoxetine will be increased to 40mg, reassured and encouraged that the goals they set can be achieved. At the three months follow-up we will re-administer the PHQ-9 and again calculate treatment response defined as \< 50% improvement (primary outcome). Non-responders will be re-evaluated by the nurse to enforce adherence to the antidepressant medication and Fluoxetine will be increased by 20mg
- DRUG
-
Sertraline Pill
The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 50mg Sertraline for all breastfeeding women instead of Fluoxetine. The nurse will then dispense the antidepressants for two weeks.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study visit, Sertraline will be increased to 100mg, reassured and encouraged that the goals they set can be achieved. At the three months follow-up we will re-administer the PHQ-9 and again calculate treatment response defined as \< 50% improvement (primary outcome). Non-responders will be re-evaluated by the nurse to enforce adherence to the antidepressant medication, and Sertraline will be increased by 50mg
- BEHAVIORAL
-
Friendship Bench Intervention- Problem Solving Therapy
The Friendship Bench Problem-solving therapy is an evidence-based intervention for depression delivered by Lay Health Workers according to an established manual. Patients are encouraged to come up with a list of their problems, to select one problem they want to tackle, brainstorm for solutions, identify the best solution, and develop an action plan to implement it until the next session. Each session consists of four stages, namely kuvhura pfungwa (opening the mind), kusimudzira (uplifting), kusimbisa (strengthening) and kusimbisisa (re-strengthening). The LHW helps patients to recognize potentially dysfunctional problem-solving and develop a realistic plan for the successful resolution of the prioritized problem. Participants are reassured and encouraged that the goals they set can be achieved. The sessions will be delivered approximately one week apart
Sponsors & Collaborators
-
University of Zimbabwe
collaborator OTHER -
Swiss National Science Foundation
collaborator OTHER -
University of Bern
lead OTHER
Principal Investigators
-
Monika Mueller, MD, PhD · University of Bern
-
Dickson Chibanda, MD, PhD · University of Zimbabwe
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-06-26
- Primary Completion
- 2027-12-28
- Completion
- 2028-02-28
Countries
- Zimbabwe
Study Locations
More Related Trials
-
A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)
NCT00275197 ·Status: COMPLETED ·Phase: PHASE2
-
Sustaining Remission of Psychotic Depression
NCT01427608 ·Status: COMPLETED ·Phase: PHASE4
-
Interpersonal Psychotherapy for Treatment Resistant Depression
NCT01896349 ·Status: UNKNOWN ·Phase: NA
-
Interpersonal Psychotherapy for Severely Depressed Inpatients
NCT00325000 ·Status: TERMINATED ·Phase: NA
-
Antidepressant Discontinuation in Treatment Resistant Depression
NCT03786614 ·Status: UNKNOWN ·Phase: NA
-
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
NCT00232167 ·Status: TERMINATED ·Phase: PHASE3
-
A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}
NCT02358343 ·Status: COMPLETED ·Phase: PHASE3
-
Ziprasidone and Sertraline in PTSD
NCT00248261 ·Status: TERMINATED
-
The Effects of Sertraline on Depression in Parkinson's Disease
NCT01437189 ·Status: COMPLETED ·Phase: NA
-
Effects of Sertraline on Brain Connectivity in Adolescents With OCD
NCT02797808 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Benefits of Switching Antidepressants Following Early Nonresponse
NCT00519012 ·Status: UNKNOWN ·Phase: PHASE4
-
Treatment of Post-Traumatic Brain Injury (TBI) Depression
NCT00233103 ·Status: COMPLETED ·Phase: PHASE2
-
Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder
NCT00143091 ·Status: TERMINATED ·Phase: PHASE2
-
Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression
NCT00001483 ·Status: COMPLETED ·Phase: PHASE2
-
A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.
NCT00636246 ·Status: COMPLETED ·Phase: PHASE2
-
Disposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria
NCT07110831 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
NCT06827431 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Stepped Care AiTBS 2 Depression Study (Ghent)
NCT03288675 ·Status: COMPLETED ·Phase: NA
-
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306 ·Status: RECRUITING ·Phase: PHASE3
-
Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia
NCT01032083 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Sertraline to Prevent PTSD
NCT00182078 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Postpartum Depression With Psychotherapy and Add-on Sertraline
NCT01028482 ·Status: COMPLETED ·Phase: NA
-
Open-Label Placebo for the Treatment of Depression
NCT02666989 ·Status: UNKNOWN ·Phase: NA
-
Discontinuation of Antidepressant Medication in Primary Care.
NCT03361514 ·Status: COMPLETED ·Phase: NA
-
Study of Fluoxetine in Adults With Autistic Disorder
NCT00027404 ·Status: COMPLETED ·Phase: NA